New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
18:31 EDTPCL, ARWR, IDTI, CGNX, TCPC, AFOP, DRI, AMKR, EMN, HLF, MAS, HLSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cognex (CGNX), up 16.4% after reporting second quarter results and third quarter revenue guidance above analyst expectations... HealthSouth (HLS), up 7.4% after reporting second quarter results and increasing fiscal 2014 EPS and Adjusted EBITDA guidance... Amkor Technology (AMKR), up 6.4%... Integrated Device (IDTI), up 7.6% after reporting first quarter results... Masco (MAS), up 4.8%. ALSO HIGHER: Darden Restaurants (DRI), up 4.6% following the company's announcement that chairman and CEO Clarence Otis will step down and the board will separate the chairman and CEO roles, appointing lead independent director Charles Ledsinger, Jr., as independent non-executive chairman... Arrowhead Research (ARWR), up 16.5% following positive comments made by CEO Christopher Anzalone, Ph.D. in an interview on CNBC. DOWN AFTER EARNINGS: Herbalife (HLF), down 11.5% after reporting disappointing second quarter results and giving guidance for the third quarter and fiscal 2014... Alliance Fiber Optic (AFOP), down 9.7%... Plum Creek Timber (PCL), down 2.8%... Eastman Chemical (EMN), down fractionally after reporting quarterly results. ALSO LOWER: TCP Capital (TCPC), down 3.1% after filing to sell $5.4M shares of common stock.
News For CGNX;HLS;AMKR;IDTI;MAS;DRI;ARWR;HLF;AFOP;PCL;EMN;TCPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
16:12 EDTDRIDarden reports Q2 Olive Garden SSS were up 0.5%
Subscribe for More Information
16:10 EDTDRIDarden narrows FY15 EPS view to $2.25-$2.30 from $2.22-$2.30, consensus $2.26
This reflects the expectation that the company's combined U.S. same-restaurant sales growth this fiscal year will be 1% to 2% and the impact of a 53rd operating week in the fiscal year. The current earnings expectations for the year also reflect anticipated support cost savings of $10M from the support cost reductions announced in the second quarter offset by cost pressures related to beef and dairy.
16:07 EDTDRIDarden reports Q2 EPS 28c, consensus 27c
Subscribe for More Information
15:42 EDTDRINotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include HEICO (HEI), consensus 46c; Darden Restaurants (DRI), consensus 27c; Five Star Quality Care (FVE), consensus (3c).
13:01 EDTAMKRAmkor Technology licenses copper pillar wafer bump technology to GLOBALFOUNDRIES
Subscribe for More Information
08:17 EDTEMNEastman Chemical initiated with a Neutral at Nomura
Subscribe for More Information
06:03 EDTHLFHerbalife insider trading case dismissed by SEC, NY Post reports
Subscribe for More Information
December 15, 2014
15:21 EDTDRINotable companies reporting before tomorrow's open
Subscribe for More Information
15:15 EDTDRIDarden technical comments before earnings
Subscribe for More Information
10:00 EDTDRIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:41 EDTDRIDarden December volatility elevated into Q2 and outlook
Subscribe for More Information
08:16 EDTDRIDarden upgraded at Telsey Advisory
Subscribe for More Information
07:33 EDTARWRArrowhead submits IND for ARC-520 to begin Phase 2b studies
Arrowhead Research announced that it submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ARC-520, itís drug candidate for the treatment of chronic hepatitis B virus infection. Arrowhead plans to submit additional clinical trial authorization applications with regulatory authorities in various jurisdictions in Europe and Asia. Pending national regulatory review and approval, Arrowhead intends to initiate two Phase 2b, multicenter, randomized, double-blind, placebo-controlled, multi-dose studies to determine the depth of hepatitis B surface antigen reduction following ARC-520 injection in combination with entecavir or tenofovir in patients with chronic immune active HBV infection. The Heparc-2002 study is planned to include patients who are negative for hepatitis B e-antigen at screening and the Heparc-2003 study is planned to include patients who are positive for HBeAg at screening. The primary objective is to evaluate the depth of HBsAg decline in response to multiple doses of ARC-520 compared to placebo in patients with chronic HBV infection as a measure of drug activity. Secondary objectives are to assess measures of safety and tolerability and to evaluate multi-dose pharmacokinetics of ARC-520 in patients with chronic HBV infection when co-administered with a fixed dose of entecavir or tenofovir, in addition to other exploratory safety and pharmacodynamic objectives.
06:08 EDTDRIDarden upgraded to Market Perform from Underperform at Telsey Advisory
December 11, 2014
13:09 EDTARWRArrowhead mentioned positively by Agora Financial
Agora Financial believes investors can "double [their] money ó virtually overnight." and have a "realistic chance" to make "up to 10 times [their] money" by investing in Arrowhead Research, according to a new research report from the firm. Arrowhead shares are up nearly 10% to $5.98 in afternoon trading. Reference Link
09:35 EDTHLFHerbalife says product claims have 'strict rules and guidelines'
Subscribe for More Information
09:34 EDTHLFVideo entitled 'Harmful Promises' posted to Ackman's Herbalife website
Subscribe for More Information
09:30 EDTEMNEastman Chemical sees 8%-12% EPS growth 2014-2017
Subscribe for More Information
December 10, 2014
14:57 EDTAMKRAmkor Technology motion to overturn ruling in Tessera suit denied
Subscribe for More Information
December 8, 2014
07:43 EDTEMNEastman Chemical remains a top pick, says UBS
UBS said Eastman Chemical remains a top pick as it continues to transform its portfolio mix. The firm expects acquired businesses to be accretive and does not believe its multiple reflects the company's transformation via M&A. UBS reiterates its Buy rating and raised its price target to $92 from $90 on Eastman Chemical shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use